The relationship between serum asymmetric dimethylarginine levels and subjective sleep quality in normotensive patients with type 2 diabetes mellitus

Alpay Aribas¹, Mehmet Kayrak¹, Mehmet Tekinalp², Hakan Akilli¹, Hayrundin Alibasic³, Serkan Yildirim¹, Mehmet Gunduz¹, Alpaslan Taner³, and Ali Unlu⁶

¹Department of Cardiology, Meram School of Medicine Hospital, Necmettin Erbakan University, Konya; ²Cardiology Clinic, Kahramanmaras Necip Fazil City Hospital, Kahramanmaras; ³Cardiology Clinic, Lokman Hekim Van Hospital, Van; ⁴Department of Cardiology, Ercis Government Hospital, Van; ⁵Department of Biochemistry, Dr Faruk Sukan Maternity and Children’s Hospital, Konya; ⁶Department of Biochemistry, Selcuk University School of Medicine, Konya, Turkey

Background/Aims: Poor sleep quality (SQ) is associated with increased cardiovascular mortality and morbidity. Additionally, asymmetric dimethylarginine (ADMA) is an independent predictor of cardiovascular mortality and morbidity. However, no sufficient data regarding the relationship between ADMA levels and SQ have been reported. The goal of the current study was to evaluate the association between SQ and ADMA levels in normotensive patients with type 2 diabetes mellitus.

Methods: The study participants consisted of 78 normotensive type 2 diabetics. The SQ of all participants was assessed using the Pittsburgh Sleep Quality Index (PSQI). Patients with a global PSQI score > 5 were defined as "poor sleepers." Factors associated with poor SQ were analyzed using a multiple regression model. Serum ADMA levels were measured using high performance liquid chromatography.

Results: The median ADMA levels of the poor sleepers were increased compared with patients defined as good sleepers (5.5 [4.2 to 6.6] vs. 4.4 [2.9 to 5.4], p < 0.01, respectively). However, the L-arginine/ADMA ratio was decreased in poor sleepers (p < 0.01). Global PSQI scores were positively correlated with ADMA levels (p < 0.01) and negatively correlated with the L-arginine/ADMA ratio (p = 0.02). ADMA levels were correlated with sleep latency (p < 0.01) and sleep efficiency (p = 0.01). Logistic regression analysis showed that ADMA levels (odds ratio [OR], 1.68; 95% confidence interval [CI], 1.16 to 2.44; p = 0.01) and body mass index (OR, 1.15; 95% CI, 1.01 to 1.31; p = 0.04) were associated with poor SQ independently of glomerular filtration rate, sex, age, duration of diabetes, hemoglobin A1c, total cholesterol, and systolic blood pressure.

Conclusions: Self-reported SQ was independently associated with ADMA levels in normotensive patients with diabetes mellitus.

Keywords: Sleep quality; N,N-dimethylarginine; Asymmetric dimethylarginine; Diabetes mellitus
INTRODUCTION

Sleep quality (SQ) is an important factor in the quality of life. Many organic diseases and sleep disorders impair SQ in different ways. Polysomnography is the best method to objectively assess SQ. However, many studies have shown that self-reported SQ also gives abundant information about a patient’s prognosis [1-3]. Subjective SQ, that is self-reported SQ, is commonly assessed using the Pittsburgh Sleep Quality Index (PSQI) scale and can be translated as the individual’s perceived SQ. It is often ignored in daily clinical practice. A poor SQ may be the forerunner of the development of coronary artery disease, hypertension, and diabetes mellitus. Moreover, poor SQ is associated with increased cardiovascular mortality and morbidity [4]. Several studies have demonstrated that poor SQ is increased 3- to 4-fold and cardiovascular disease 2- to 3-fold in individuals with diabetes mellitus compared with those without diabetes mellitus [5]. An organic basis for this relationship has not yet been clearly demonstrated.

Several studies in the literature have indicated that increased levels of inflammatory markers such as high-sensitivity C-reactive protein, interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), and E-selectin are related to poor SQ in the general population [6-8]. Elevated inflammatory markers, such as IL-6 and soluble intercellular adhesion molecule, were associated with an increased morbidity and mortality in apparently healthy men, as reported by Ridker et al. [9]. The relationship between inflammation and poor SQ has been reported in various studies [6-8]. The association of self-reported SQ and sleep duration with IL-6, IL-1β, and TNF-α levels among a community sample of 156 healthy adults was examined, and it was determined that poor SQ is associated with a greater production of all three of these inflammatory mediators. Pro-oxidant and proinflammatory conditions inhibit the activity of dimethylarginine dimethylaminohydrolase, which metabolizes asymmetric dimethylarginine (ADMA). It has been demonstrated that ADMA plasma levels are elevated in subclinical inflammation states, including patients with multiple risk factors for atherosclerosis. Therefore, we hypothesized that poor SQ may be related to increased ADMA levels.

The current studies have focused on the above-mentioned question. However, diabetes mellitus is an important contributor to both poor SQ and cardiovascular mortality. ADMA, an endogenous nitric oxide inhibitor, is commonly increased among patients with type 2 diabetes mellitus [10], and it is an independent predictor of cardiovascular mortality and morbidity in patients with diabetes mellitus [11]. However, the relationship between SQ and ADMA among patients with type 2 diabetes mellitus has yet to be investigated. Therefore, our goal was to investigate the relationship between SQ and ADMA levels among patients with type 2 diabetes mellitus.

METHODS

Patient selection

In this cross-sectional study, 78 normotensive patients with type 2 diabetes mellitus (male:female, 30:48) were enrolled. Patients who presented to the endocrinology outpatient clinic for routine glycemic control were selected for the study. All patients included in this study had been diagnosed with type 2 diabetes mellitus for a minimum of 6 months prior to enrolling in the study. This study was approved by the local Ethics Committee and adhered to the Declaration of Helsinki. Written informed consent was obtained from all patients participating in the study.

Exclusion criteria included patients with any of the following: hypertension, antihypertensive medication use, coronary artery disease, previous myocardial infarction, revascularization history, valvular heart disease, left ventricular segmental wall motion abnormality, ejection fraction below 50%, dysrhythmias such as atrial fibrillation, pulmonary disease, renal or hepatic dysfunction, any systemic disorder, nocturia, severe obesity (body mass index [BMI] > 35), known sleep apnea, a score ≥ 8 on the Epworth Sleepiness Scale, psychiatric medication use, alcohol abuse, and an evening occupation, such as security guards and long-distance drivers. Patients on hypnotics or any medications directly affecting SQ were also excluded from the study. Cases of silent myocardial ischemia, as diagnosed by a treadmill stress test, were excluded. A positive stress test was defined as a horizontal and/or down-sloping ST segment depression above 1 mm in two consecutive leads. A flow-chart diagram of the study population is shown in Fig. 1.
Study protocol
Type 2 diabetes mellitus subjects were questioned regarding a history of hypertension. Blood pressure (BP) was measured twice in the office, with a 10-minute resting interval in between, using a mercury sphygmomanometer (ERKA D-83646 Bad Tolz, Kallmeyer Medizintechnik GmbH Co. KG, Bad Tolz, Germany). Patients with a BP < 140/90 mmHg, who were not taking any antihypertensive medications, were asked to evaluate their quality of sleep using the PSQI questionnaire. After a 10-hour fast, blood samples were obtained from all patients in the morning the following day between 9:00 and 11:00 AM. Blood samples were stored at –80°C, and ADMA and L-arginine were measured in these samples at the end of the study using high performance liquid chromatography. Other routine biochemical tests, including a complete blood count and metabolic panel, were analyzed on the same day as the blood draw.

The interassay coefficient of variation (CV) of ADMA was calculated as 6.6%, the intra-assay CV as 4.7%, and the imprecision of the assay as < 10%. Additionally, the CV values of L-arginine were evaluated. The inter-assay CV of L-arginine was calculated as 7.6%, the intra-assay CV as 5.5%, and the imprecision of the assay as < 10%. All tests were performed in duplicate.

Sleep assessment
SQ was measured using the PSQI [12]. This self-reported questionnaire assesses SQ and contains 19 self-rated questions that aid in differentiating SQ. The PSQI is comprised of seven components: subjective SQ, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medications, and daytime drowsiness and dysfunction. Each component is scored from 0 to 3, yielding a global PSQI score between 0 and 21. Higher scores indicate a lower SQ. A global PSQI score greater than 5 has an 89.6% sensitivity and an 86.5% specificity in identifying patients with poor versus good SQ [12].

Blood sample analyses
For ADMA analysis, peripheral venous blood samples (5 cc) were collected in Vacutainer tubes without anticoagulant. The tubes were centrifuged immediately at 3,000 × g for 10 minutes. The separated serum samples were stored at –80°C. Measurement of ADMA was accomplished using high performance liquid chromatography (HP Agilent 1200, Agilent Technologies, Palo Alto, CA, USA), with modification of the method described by Chen et al. [13]. GFR was calculated from serum creatinine measurements using the Cockcroft-Gault formula [14].

Statistical analyses
All data were analyzed using SPSS version 15.0 (SPSS Inc., Chicago, IL, USA). The distribution of variables was analyzed using the Kolmogorov-Smirnov test. Normally distributed data are presented as means ± standard deviations. Data with abnormal distributions are expressed as medians (interquartile range), and dichotomous data are presented as percentages. The significance level of the differences between two groups was assessed using independent Student t tests for normally distributed variables and the non-parametric Mann Whitney U test for non-normally distributed variables.
The differences between the categorical variables were determined using the chi-square test. Linear association between parametric variables was evaluated using Pearson correlation test. Correlation analysis of non-parametric data was performed using the Spearman test. Stepwise multivariate logistic regression was analyzed to determine the factors associated with poor SQ (PSQI > 5). The level of statistical significance was accepted as \( p < 0.05 \) for all tests.

Power analysis was performed using the Minitab 16 packet program. The sample size was calculated as 70 to determine a difference in ADMA of approximately 1.0 \( \mu \text{mol/L} \) with 80% power and 95% confidence interval (CI). The study sample was enlarged by approximately 10% to counteract a potential loss of data during the blood sample analysis. A MedCalc 9.2.0.1 packet program was used to calculate receiver operating characteristic curves and to analyze specificity, sensitivity, nega-

### Table 1. Baseline characteristics of the sleep quality groups

| Variable                        | Good sleep quality (n = 47) | Poor sleep quality (n = 31) | \( p \) value |
|---------------------------------|----------------------------|----------------------------|--------------|
| Age, yr                         | 47.7 ± 9.4                 | 50.6 ± 9.2                 | 0.21         |
| Female sex (number)             | 29 (62)                    | 19 (61)                    | 0.91         |
| Smoking (number)                | 8 (17)                     | 6 (19)                     | 0.84         |
| Height, cm (mean ± SD)          | 163 ± 10                   | 162 ± 9                    | 0.67         |
| Weight, kg (mean ± SD)          | 76 ± 8                     | 79 ± 10                    | 0.26         |
| Body mass index, kg/m² (mean ± SD) | 28.8 ± 3.4                | 30.2 ± 4.5                 | 0.16         |
| Waist circumference, cm         | 100 ± 13                   | 100 ± 8                    | 0.90         |
| Hip circumference, cm           | 106 ± 9                    | 106 ± 9                    | 0.92         |
| Duration of diabetes, yr (mean ± SD) | 6.0 (2.5–12)            | 6.0 (2.0–9.0)              | 0.68         |
| ADMA, \( \mu \text{mol/L} \) (mean) | 4.4 (2.9–5.4)           | 5.5 (4.2–6.6)              | 0.01         |
| L-arginine/ADMA ratio (mean ± SD) | 42.0 (31.4–54.3)       | 35.1 (27.8–41.1)           | 0.01         |
| Fasting glucose, mg/dL (mean ± SD) | 164 ± 70                 | 172 ± 62                   | 0.65         |
| Hemoglobin A1C, % (mean ± SD)   | 7.5 ± 1.5                  | 7.1 ± 1.4                  | 0.27         |
| Hemoglobin, g/dL (mean ± SD)    | 13.8 ± 1.4                 | 14 ± 1.2                   | 0.62         |
| White blood cell, K/uL (mean ± SD) | 7.6 (6.4–9.6)            | 7.7 (6.6–8.5)              | 0.90         |
| Total cholesterol, mg/dL (mean ± SD) | 194 ± 40                 | 205 ± 31                   | 0.26         |
| LDL-C, mg/dL (mean ± SD)        | 118 ± 35                   | 125 ± 22                   | 0.23         |
| HDL-C, mg/dL (mean ± SD)        | 42 ± 10                    | 41 ± 10                    | 0.90         |
| Triglycerides, mg/dL (mean ± SD) | 172 ± 80                   | 196 ± 102                  | 0.28         |
| Urea, mg/dL (mean ± SD)         | 22.6 ± 7.2                 | 25 ± 9.7                   | 0.32         |
| Creatinine, mg/dL (mean ± SD)   | 0.70 ± 0.2                 | 0.73 ± 0.2                 | 0.43         |
| GFR, mL/min/1.73 m² (mean ± SD) | 127 ± 27                   | 123 ± 26                   | 0.51         |
| Systolic blood pressure, mmHg (mean ± SD) | 123 ± 14                | 121 ± 11                   | 0.38         |
| Diastolic blood pressure, mmHg (mean ± SD) | 79 ± 9                   | 77 ± 9                     | 0.47         |
| Pittsburgh Sleep Quality Index (mean ± SD) | 2.6 ± 1.3               | 8.2 ± 1.8                  | 0.01         |

Values are presented as mean ± SD, number (%), or median (interquartile range). ADMA, asymmetric dimethylarginine; LDL-C, low density lipoprotein cholesterol; HDL-C, high density lipoprotein cholesterol; GFR, glomerular filtration rate.

http://dx.doi.org/10.3904/kjim.2015.30.3.316


**RESULTS**

The baseline characteristics of the poor SQ and good SQ groups are shown in Table 1. ADMA levels of the poor sleepers were increased compared with the good sleepers ($p < 0.01$). In addition, the L-arginine/ADMA ratio was lower in poor sleepers than in good sleepers ($p < 0.01$). Other parameters, such as duration of type 2 diabetes mellitus diagnosis, hemoglobin A1c (HbA1c) and other laboratory findings, were comparable between the two groups (Table 1).

When linear associations were evaluated, it was determined that the global PSQI was correlated with ADMA levels ($p < 0.01$) (Fig. 2) and inversely correlated with the L-arginine/ADMA ratio ($p = 0.02$) (Table 2). ADMA levels were also correlated with both sleep latency ($p < 0.01$) and sleep efficiency ($p < 0.01$) (Table 2). Similarly, the L-arginine/ADMA ratio was inversely correlated with sleep latency ($p < 0.01$), the global PSQI, and sleep efficiency ($p = 0.02$) (Table 2). The global PSQI was not correlated with demographics or other laboratory findings (Table 3).

In stepwise multivariate logistic regression analysis, the ADMA level was associated with poor SQ (odds ratio [OR], 1.68; 95% CI, 1.16 to 2.44; $p = 0.01$), independently of GFR, sex, age, BMI, duration of diabetes, HbA1c, total cholesterol, and systolic BP. Additionally, body mass index was also associated with poor SQ (OR, 1.15; 95% CI, 1.01 to 1.31; $p = 0.04$) (Table 4). However, ADMA was not correlated with BMI ($r = -0.17$, $p = 0.17$).

A cut-off value was examined to determine the positive predictive value for poor SQ. The optimal cutoff value was determined to be $> 5.36 \mu mol/L$ ADMA using the MedCalc 9.2.01 program, and the area under the curve was found to be 0.72 (standard error = 0.060, $p < 0.01$) for this cutoff value. The following results were obtained using the cutoff value $> 5.36 \mu mol/L$ ADMA: sensitivity, 62.5%; specificity, 77.5%; positive predictive value, 64.5%; and negative predictive value, 76% (Fig. 3).

![Figure 2. Correlation between asymmetric dimethylarginine (ADMA) and Pittsburgh Sleep Quality Index (PSQI).](http://dx.doi.org/10.3904/kjim.2015.30.3.316)

| Variable            | ADMA       | L-arginine/ADMA ratio |
|---------------------|------------|-----------------------|
|                     | $r^a$      | $p$ value$^b$         | $r^a$      | $p$ value$^b$         |
| PSQI                | 0.39$^c$   | 0.01                  | -0.28$^d$  | 0.02                  |
| Sleep duration      | 0.08       | 0.49                  | -0.01      | 0.94                  |
| Sleep latency       | 0.40$^c$   | 0.01                  | -0.33$^c$  | -0.01                 |
| Actual sleep time   | -0.09      | 0.41                  | 0.13       | 0.25                  |
| Sleep efficiency    | -0.30$^c$  | 0.01                  | 0.26$^d$   | 0.02                  |

ADMA, asymmetric dimethylarginine; PSQI, Pittsburgh Sleep Quality Index.

*aSpearman correlation coefficient.

*bLevel of statistical significance.

*cCorrelation is significant at the 0.01 level (two-tailed).

*dCorrelation is significant at the 0.05 level (two-tailed).
DISCUSSION

We determined that serum ADMA levels were significantly increased in patients considered poor sleepers, and that ADMA levels can serve as an independent factor associated with poor SQ in normotensive patients with type 2 diabetes mellitus. Linear relationships between ADMA levels and SQ parameters were also observed. To the best of our knowledge, this is the first study to examine the association between self-reported SQ and ADMA levels in this population.

There are conflicting results about the relationship between poor SQ and glycemic control in patients with type 2 diabetes mellitus [3,15]. Knutson et al. [15] reported that lower SQ is associated with poorer glucose control after controlling for age, sex, BMI, insulin use, and the presence of major complications. Also, Tsai et al. [3] showed a strong positive association between poor SQ and HbA1c level after adjusting for a large number of possible confounders. We did not observe any relation between ADMA levels and HbA1c. Mean HbA1c values were above 8% in the aforementioned studies, while they were approximately 7% in the current study. Therefore, relatively good glycemic control may explain our particular finding regarding the relationship between HbA1c and SQ. Similarly, we also did not detect a relationship between HbA1c and ADMA in the present study. The relationship between ADMA levels and glycemic control has exhibited controversial results in the literature [3,15-18]. Can et al. [16] showed that patients with type 2 diabetes mellitus and poor glycemic control had higher ADMA concentrations than patients with well-controlled glycemia. In contrast, Paiva et al. [17] reported that ADMA levels were inversely related to HbA1c levels in patients with type 2 diabetes mellitus due to renal hyperfiltration. Also, Marcovecchio et al.

Table 3. Correlation with global Pittsburgh Sleep Quality Index score and other variables

| Variable            | r     | p value |
|---------------------|-------|---------|
| Age                 | 0.23  | 0.06    |
| Body mass index     | 0.02  | 0.87    |
| Duration of diabetes| 0.01  | 0.94    |
| Fasting glucose     | −0.01 | 0.95    |
| Hemoglobin A1c      | −0.14 | 0.26    |
| Creatinine          | 0.18  | 0.16    |

Table 4. Stepwise logistic regression results for the relationship between sleep quality and other variables

| 1. Step | B         | OR (95% CI)       | p value |
|---------|-----------|-------------------|---------|
| Asymmetric dimethylarginine | 0.55 | 1.76 (1.10–2.74) | 0.01    |
| Glomerular filtration rate | −0.01 | 0.98 (0.96–1.01) | 0.30    |
| Female sex | 0.18 | 0.92 (0.22–3.84) | 0.91    |
| Age | 0.01 | 0.98 (0.89–1.08) | 0.68    |
| Body mass index | 0.16 | 1.17 (0.98–1.40) | 0.06    |
| Duration of diabetes | −0.03 | 0.97 (0.85–1.11) | 0.67    |
| Hemoglobin A1c | −0.22 | 0.80 (0.47–1.37) | 0.43    |
| Total cholesterol | 0.01 | 1.00 (0.98–1.02) | 0.93    |
| Systolic blood pressure | −0.03 | 0.97 (0.93–1.01) | 0.07    |
| Insulin user | 0.57 | 1.76 (0.47–6.62) | 0.40    |

| 6. Step | B         | OR (95% CI)       | p value |
|---------|-----------|-------------------|---------|
| Asymmetric dimethylarginine | 0.52 | 1.68 (1.16–2.44) | 0.01    |
| Body mass index | 0.14 | 1.15 (1.01–1.31) | 0.04    |
| Systolic blood pressure | −0.03 | 0.97 (0.93–1.00) | 0.06    |

R² = 0.29 model statistics p = 0.04.
OR, odds ratio; CI, confidence interval.
showed a negative association between HbA1c and ADMA in young people with type 1 diabetes due to the down-regulation of ADMA production or stimulation of its metabolism. As a result, HbA1c levels were not related to either ADMA levels or SQ. ADMA is also associated with obesity [19]. Hung et al. [19] demonstrated that female gender, being overweight, obesity, and sleep duration were associated with poor SQ independently of cardiometabolic risk factors. It has been recommended that subjects who are obese or overweight be evaluated for the presence of sleep disturbance [19]. We found BMI to be an independent factor associated with poor SQ (OR, 1.15; 95% CI, 1.01 to 1.31; \( p = 0.04 \)) in logistic regression analysis. Despite exclusion of severely obese individuals with a BMI > 35 kg/m², BMI remained associated with poor SQ. ADMA levels are increased in obesity [20], yet, we did not find a linear association between serum ADMA levels and BMI. Koc et al. [20] reported that ADMA levels were significantly higher in obese individuals compared with healthy controls. In the study by Koc et al. [20], the mean BMI was 35.0 ± 3.3 in the obese group, while in the current study, it was 29.4 ± 3.5. Considering that severely obese subjects were excluded from the present study, it is likely that an obvious relationship between BMI and ADMA has been diminished. Although BMI was not correlated with ADMA levels, BMI was still determined to be an independent factor associated with poor SQ in the current study. One possible explanation for this is that BMI may utilize an ADMA-independent pathway in the impairment of SQ.

Although no significant observation in regards to a relationship with BP and SQ was found between the two groups, a trend was observed demonstrating an inverse relationship with BP and SQ using logistic regression analysis. This suggests that a lower BP in type 2 diabetes mellitus patients does not enhance SQ. Subjective SQ deteriorates with aging; however, there is also an increase in the incidence of diseases, such as atherosclerotic heart disease, and hypertension, with aging [21]. Vitiello et al. [21] showed that asymptomatic older adults manifested a significantly greater amount of disturbed sleep compared with healthy, younger subjects. We also observed an association between increasing age and poor SQ in the present study (\( p = 0.06 \)). However, while the mean age of the patients in the study of Vitiello et al. [21] was 67.5 ± 0.5 years, the mean age of the patients in the current study was approximately 50 years. Therefore, we believe that a possible relationship between age and poor SQ may be masked by the relatively younger age of the patients in the present study.

The pathophysiological mechanisms of the association between poor SQ and poor cardiovascular outcome have not been fully elucidated in patients without overt obstructive sleep apnea syndrome. There are some reports citing a relationship between sympathetic hyperactivation and poor SQ [22,23]. Poor SQ may lead to sympathetic hyperactivation via disturbances in the normal circadian variation of the autonomic nervous system. Additionally, there are some data suggesting that sympathetic neural activation and ADMA may affect the level of each other [24,25]. As seen in the aforementioned studies, both ADMA levels and SQ have been individually linked to sympathetic hyperactivation, suggesting that the potential mechanism contributing to the association between poor SQ and serum ADMA levels may be the sympathetic hyperactivation induced by poor SQ [4,5,21,24,25]. However, we did not examine sympathetic activation in the current study, which may contribute to the mechanisms behind serum ADMA levels and poor SQ relationship.
Limitations
An important limitation of the present study was the unavailability of polysomnographic data. Although a strong correlation between actigraphy and subjective assessment was shown with changes in sleep patterns in the study by Lockley et al. [26], there are some discrepancies between the two methods. Additionally, ADMA levels are high in patients with obstructive sleep apnea syndrome, and the subjects in this study were not evaluated for the presence of obstructive sleep apnea syndrome. However, the Epworth Sleepiness Scale was performed on all patients, and this scale is often used clinically to screen for manifestations of the behavioral morbidity associated with obstructive sleep apnea syndrome. Rosenthal and Dolan [27] reported that an Epworth Sleepiness Scale score of 10 has a 66% sensitivity and a 48% specificity, and a score of 8 on the Epworth Sleepiness Scale has a 76% sensitivity and a 31% specificity for obstructive sleep apnea syndrome with an apnea-hypopnea index of ≥ 5. Therefore, we chose 8 as our Epworth Sleepiness Scale cutoff score for excluding patients from the present study. Using this method, our goal was to exclude obstructive sleep apnea syndrome patients from the study. Another limitation is that one of the probable causes of sleep problems is depression, and the level of depression was not measured in our study. Effort stress tests were performed in all patients to exclude any unknown coronary artery disease. However, since the sensitivity and specificity of an effort stress test varies from 45% to 67% and from 72% to 90% respectively [28], some patients with coronary artery disease may have not been detected. Other markers of inflammation, leptin, and the sympathetic activation parameters and their relationships with ADMA could not be evaluated due to a limited budget. However, we chose to perform ADMA measurements because the American College of Cardiology/American Heart Association guidelines advise the use of ADMA levels for screening CV risk in asymptomatic diabetic subjects. Thus, ADMA is a well-studied and accepted biomarker for CV risk screening in diabetic subjects. Lastly, the sample size of the study was relatively small, but the power of the study was determined to be acceptable.

KEY MESSAGE
1. A possible link between asymmetric dimethylarginine levels and poor sleep quality (SQ) in patients with type 2 diabetes mellitus.
2. It provides insight into the mechanism(s) by which poor SQ and adverse health outcomes occur in patients with type 2 diabetes mellitus.

Conflict of interest
No potential conflict of interest relevant to this article was reported.

Acknowledgments
This project was supported by Selcuk University Scientific Research Projects Fund.

REFERENCES
1. Martin JL, Fiorentino L, Jouldjian S, Mitchell M, Josephson KR, Alessi CA. Poor self-reported sleep quality predicts mortality within one year of inpatient post-acute rehabilitation among older adults. Sleep 2011;34:1715-1721.
2. Brekke FB, Waldum B, Amro A, et al. Self-perceived quality of sleep and mortality in Norwegian dialysis patients. Hemodial Int 2014;18:87-94.
3. Tsai YW, Kann NH, Tung TH, et al. Impact of subjective sleep quality on glycemic control in type 2 diabetes mellitus. Fam Pract 2012;29:30-35.
4. Dew MA, Hoch CC, Buyssse DJ, et al. Healthy older adults’ sleep quality on glycemic control in type 2 diabetes mellitus. Fam Pract 2012;29:30-35.
5. Almdal T, Scharling H, Jensen JS, Vestergaard H. The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med 2006;166:1422-1426.
6. Irwin MR, Wang M, Campomayor CO, Collado-Hidalgo A, Cole S. Sleep deprivation and activation of morning levels of cellular and genomic markers of inflammation. Arch Intern Med 2006;166:1759-1762.
7. Friedman EM. Sleep quality, social well-being, gender, and inflammation: an integrative analysis in a national sample. Ann N Y Acad Sci 2011;1231:23-34.
8. Chiu YL, Chuang YF, Fang KC, et al. Higher systemic
inflammation is associated with poorer sleep quality in stable haemodialysis patients. Nephrol Dial Transplant 2009;24:247-251.

9. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 1998;351:88-92.

10. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-1203.

11. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007;30:1834-1839.

12. Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989;28:193-213.

13. Chen BM, Xia LW, Zhao RQ. Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;692:467-471.

14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.

15. Knutson KL, Ryden AM, Mander BA, Van Cauter E. Role of sleep duration and quality in the risk and severity of type 2 diabetes mellitus. Arch Intern Med 2006;166:1768-1774.

16. Can A, Bekpinar S, Gurdol F, Tutuncu Y, Unlucerci Y, Dinccag N. Dimethylarginines in patients with type 2 diabetes mellitus: relation with the glycaemic control. Diabetes Res Clin Pract 2011;94:61-64.

17. Paiva H, Lehtimaki T, Laakso J, et al. Plasma concentrations of asymmetric-dimethyl-arginine in type 2 diabetes associate with glycaemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 2003;52:303-307.

18. Marocvecchio ML, Widmer B, Turner C, Dunger DB, Dalton RN. Asymmetric dimethylarginine in young people with type 1 diabetes: a paradoxical association with HbA1c. Diabet Med 2011;28:685-691.

19. Hung HC, Yang YC, Ou HY, Wu JS, Lu FH, Chang CJ. The association between self-reported sleep quality and overweight in a Chinese population. Obesity (Silver Spring) 2013;21:486-492.

20. Koc F, Tokac M, Erdem S, et al. Serum asymmetric dimethylarginine levels in normotensive obese individuals. Med Sci Monit 2010;16:CR536-CR539.

21. Vitiello MV, Larsen LH, Moe KE. Age-related sleep change: gender and estrogen effects on the subjective-objective sleep quality relationships of healthy, non-complaining older men and women. J Psychosom Res 2004;56:503-510.

22. Huang Y, Mai W, Hu Y, et al. Poor sleep quality, stress status, and sympathetic nervous system activation in non-dipping hypertension. Blood Press Monit 2011;16:117-123.

23. de Zambotti M, Covassin N, Sarlo M, De Min Tona G, Trinder J, Stegagno L. Nighttime cardiac sympathetic hyper-activation in young primary insomniacs. Clin Auton Res 2013;23:49-56.

24. Augustyniak RA, Victor RG, Morgan DA, Zhang W. L-NAME- and ADMA-induced sympathetic neural activation in conscious rats. Am J Physiol Regul Integr Comp Physiol 2006;290:R726-R732.

25. Hijmering ML, Stroes ES, Olijhoek J, Hutten BA, Blankestijn PJ, Rabelink TJ. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol 2002;39:683-688.

26. Lockley SW, Skene DJ, Arendt J. Comparison between subjective and actigraphic measurement of sleep and sleep rhythms. J Sleep Res 1999;8:175-183.

27. Rosenthal LD, Dolan DC. The Epworth sleepiness scale in the identification of obstructive sleep apnea. J Nerv Ment Dis 2008;196:429-431.

28. Gibbons RJ, Chatterjee K, Daley J, et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 1999;33:2092-2197.